Back to all blog posts
Aiforia Technologies Plc, Press Release, March 21, 2025 at 2:00 p.m. EET
Aiforia Technologies, a pioneer in AI-driven diagnostics in pathology, has announced a new partnership with PathPresenter. This collaboration aims to broaden the reach and adoption of Aiforia’s AI-powered image analysis solutions by utilizing PathPresenter's comprehensive pathology workflow platform. By combining their distinct expertise in digital pathology, the companies aim to provide pathologists with enhanced diagnostic capabilities and streamlined end-to-end workflow management solutions.
"This partnership with PathPresenter is a significant step in expanding the reach of Aiforia's AI solutions in the United States. PathPresenter's widely used platform connects pathologists globally and provides access to valuable expertise and best-in-class tools. By integrating our technologies, we will enable pathologists to seamlessly access and utilize Aiforia's AI solutions for image analysis, aiming to improve the speed and accuracy of the diagnostic workflows,” says Jukka Tapaninen, CEO of Aiforia.
"PathPresenter is committed to providing pathologists with the most comprehensive and advanced tools for collaboration and diagnosis. By integrating Aiforia's cutting-edge image analysis solutions, such as AI models for breast, lung and prostate cancer, we enhance our users' ability to connect with colleagues, access expertise, and utilize AI models within their existing workflows - ultimately aiming to empower pathologists and improve patient care,” says Patrick Myles, CEO of PathPresenter."
Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/
Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi
About Aiforia
Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.
Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient. Selected Aiforia® Clinical AI models and the Aiforia® Clinical Suite Viewer are CE-IVD marked for diagnostic use in EU and EEA countries; see the full list at www.aiforia.com/aiforia-clinical-solutions. In all other countries, including the United States, the use is limited to Research Use Only.
Find out more at www.aiforia.com
About PathPresenter
PathPresenter is an enterprise image management and workflow platform for digital pathology. We are on a mission to democratize access to the world's pathology knowledge by connecting pathologists to the vast expertise of their colleagues globally and providing a practical platform to access and use best-in-class AI models. Founded by dermatopathologist and digital pathology pioneer Dr. Rajendra Singh, PathPresenter's secure, scalable, vendor-agnostic enterprise pathology workflow software has been adopted by tier one medical institutions for clinical care, education, and research, and the company has built a thriving community of tens of thousands of users around the world to easily view and share digital pathology images and knowledge.
The PathPresenter Clinical Viewer is a digital pathology image viewing and management software. It is approved for research use only and has not been cleared by the FDA as a medical device. It is the responsibility of a qualified pathologist to employ appropriate procedures and safeguards to assure the validity of the interpretation of images obtained using this device. Pathologists should exercise professional judgment in each clinical situation and examine the glass slides by conventional microscopy if there is doubt about the ability to accurately render an interpretation using this device alone.
Learn more at www.pathpresenter.com.